Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828365 | 0.87 | ADORA3 (0.51) | ADORA2AADORA3ADORA1ADORA2BHPGD | |
| SCHEMBL23828418 | 0.86 | FYN (0.47) | ADORA2AADORA3ADORA1ADORA2BPIK3CG | |
| SCHEMBL23828526 | 0.85 | PIK3CG (0.45) | ADORA2AADORA3ADORA1PIK3CG | |
| SCHEMBL23828495 | 0.79 | TP53 (0.46) | ADORA2AADORA3ADORA1KDM4EHSD17B10 | |
| SCHEMBL23828334 | 0.78 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2BPIK3CG | |
| SCHEMBL23828484 | 0.78 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2BPIK3CG | |
| SCHEMBL23828557 | 0.77 | AOC3 (0.47) | ADORA2AADORA3PIK3CGKDM4EPTGS2 | |
| SCHEMBL23828565 | 0.76 | KDM4E (0.46) | ADORA2AADORA1KDM4EHSD17B10HPGD | |
| SCHEMBL23828531 | 0.75 | ADORA2A (0.57) | ADORA2AADORA3ADORA1ADORA2BPIK3CG | |
| SCHEMBL23828425 | 0.75 | PIK3CG (0.46) | ADORA3PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | claimed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | claimed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | claimed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | claimed |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.